Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: Role of NKG2D-dependent pathway

International Immunology

Volumn 20, Issue 7, 2008, Pages 801-810

  Le Maux Chansac, Béatrice ^a   Missé, Dorothée ^b   Richon, Catherine ^c   Vergnon, Isabelle ^a   Kubin, Marek ^d   Soria, Jean Charles ^c   Moretta, Alessandro ^e   Chouaib, Salem ^a   Mami Chouaib, Fathia ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d AMGEN INC   (United States)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

NK cell activating receptors; NKG2DL; NSCLC; Tumor infiltrating NK cells

Indexed keywords

BINDING PROTEIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; NEUTRALIZING ANTIBODY; PROTEIN P46;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CELL CLONE; CELL STIMULATION; CORRELATION ANALYSIS; CYTOLYSIS; DISEASE FREE SURVIVAL; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LYMPH NODE DISSECTION; MALE; MEDIASTINUM LYMPH NODE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROSURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; TUMOR ESCAPE;

ANTIBODIES, BLOCKING; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-15; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; KYNURENINE 3-MONOOXYGENASE; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT PROTEINS;

EID: 45749134656     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn038     Document Type: Article

References (43)

1. Vitale, M., Bottino, C., Sivori, S. et al. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187:2065.
2. Pende, D., Parolini, S., Pessino, A. et al. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190:1505.
3. Pende, D., Cantoni, C., Rivera, P. et al. 2001. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J. Immunol. 31:1076.
4. Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H. and Spies, T. 1999. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96:6879.
5. Le Maux Chansac, B., Moretta, A., Vergnon, I. et al. 2005. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175:5790.
6. Echchakir, H., Mami-Chouaib, F., Vergnon, I. et al. 2001. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 61:4078.
7. Dorothee, G., Vergnon, I., Menez, J. et al. 2002. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: Role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J. Immunol. 169:809.
8. Brodsky, F. M. and Parham, P. 1982. Monomorphic anti-HLA-A, B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J. Immunol. 128:129.
9. Della Chiesa, M., Carlomagno, S., Frumento, G. et al. 2006. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108:4118.
10. Asselin-Paturel, C., Megherat, S., Vergnon, I. et al. 2001. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: Relation with interleukin-10 induction. Cancer 91:113.
11. Misse, D., Esteve, P. O., Renneboog, B. et al. 2001. HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway. Blood 98:541.
12. Werb, Z. 1997. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91:439.
13. Fiore, E., Fusco, C., Romero, P. and Stamenkovic, I. 2002. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor-cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21:5213.
14. Sultan, S., Gosling, M., Nagase, H. and Powell, J. T. 2004. Shear stress-induced shedding of soluble intercellular adhesion molecule-1 from saphenous vein endothelium. FEBS Lett. 564:161.
15. Waldhauer, I. and Steinle, A. 2006. Proteolytic release of soluble UL 16-binding protein 2 from tumor cells. Cancer Res. 66:2520.
16. Castriconi, R., Cantoni, C., Della Chiesa, M. et al. 2003. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl Acad. Sci. USA 100:4120.
17. Groh, V., Wu, J., Yee, C. and Spies, T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734.
18. Jinushi, M., Takehara, T., Tatsumi, T. et al. 2005. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J. Hepatol. 43:1013.
19. Sutherland, C. L., Chalupny, N. J., Schooley, K., VandenBos, T., Kubin, M. and Cosman, D. 2002. UL 16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168:671.
20. Lanier, L. L. 2001. A renaissance for the tumor immunosurveillance hypothesis. Nat. Med. 7:1178.
21. Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K. and Plymate, S. R. 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114:560.
22. Pence, D., Rivera, P, Marcenaro, S. et al. 2002. Major histocompatibility complex class I-related chain A and UL 16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62:6178.
23. Marten, A., von Lilienfeld-Toal, M., Buchler, M. W. and Schmidt, J. 2006. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int. J. Cancer 119:2359.
24. Xu, X., Rao, G., Gaffud, M. J. et al. 2006. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J. Clin. Endocrinol. Metab. 91:2704.
25. Busche, A., Goldmann, T., Naumann, U., Steinle, A. and Brandau, S. 2006. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum. Gene Ther. 17:135.
26. Egeblad, M. and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2:161.
27. Vihinen, P. and Kahari, V. M. 2002. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99:157.
28. Levy, A. T., Cioce, V., Sobel, M. E. et al. 1991. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 51:439.
29. MacDougall, J. R., Bani, M. R., Lin, Y, Rak, J. and Kerbel, R. S. 1995. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res. 55:4174.
30. Bergers, G., Brekken, R., McMahon, G. et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carck nogenesis. Nat. Cell Biol. 2:737.
31. Chambers, A. F., Groom, A. C. and MacDonald, I. C. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2:563.
32. Coussens, L. M., Fingleton, B. and Matrisian, L. M. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387.
33. Salih, H. R., Rammensee, H. G. and Steinle, A. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098.
34. Salih, H. R., Antropius, H., Gieseke, F. et al. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389.
35. Doubrovina, E. S.; Doubrovin, M. M., Vider, E. et al. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171:6891.
36. Friese, M. A., Wischhusen, J., Wick, W. et al. 2004. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64:7596.
37. Lee, J. C., Lee, K. M., Kim, D. W. and Heo, D. S. 2004. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172:7335.
38. Uyttenhove, C., Pilotte, L., Theate, I. et al. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269.
39. Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U. and Ferrara, G. B. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459.
40. Belardelli, F. and Ferrantini, M. 2002. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23:201.
41. Smyth, M. J., Swann, J., Kelly, J. M. et al. 2004. NKG2D recognition and perform effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200:1325.
42. Sutherland, C. L., Rabinovich, B., Chalupny, N. J., Brawand, P., Miller, R. and Cosman, D. 2006. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108:1313.
43. Roberts, A. I., Lee, L., Schwarz, E. et al. 2001. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167:5527.